Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
KEYNOTE-921
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
- NCT03834506 ↗
- Completed
- Merck Sharp & Dohme LLC
- Standard
We haven't built an HCP commentary report on KEYNOTE-921 (pembrolizumab, docetaxel and 2 more in Prostatic Neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYNOTE-921 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 14 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab; Docetaxel; Prednisone; Placebo; Dexamethasone
- Arms
- Pembrolizumab+Docetaxel · Experimental
- Placebo+Docetaxel · Placebo comparator
- Enrollment
- 1,030
- Primary outcomes
- Overall Survival (OS)
- Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- May 2, 2019
- Primary completion
- Jun 20, 2022
- Results posted
- Yes
- Registry record
- NCT03834506 · updated Jul 18, 2025
Publications
linked from the registry- Petrylak DP, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, Todenhofer T, Gurney H, Kramer G, Bergman AM, Zalewski P, De Santis M, Armstrong AJ, Gerritsen W, Pachynski R, Byun SS, Retz M, Levesque E, McDermott R, Bracarda S, Manneh R, Levartovsky M, Li XT, Schloss C, Poehlein CH, Fizazi K. Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial. J Clin Oncol. 2025 May 10;43(14):1638-1649. doi: 10.1200/JCO-24-01283. Epub 2025 Mar 5. PubMed 40043230
- Petrylak DP, Ratta R, Gafanov R, Facchini G, Piulats JM, Kramer G, Flaig TW, Chandana SR, Li B, Burgents J, Fizazi K. KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Future Oncol. 2021 Sep;17(25):3291-3299. doi: 10.2217/fon-2020-1133. Epub 2021 Jun 8. PubMed 34098744